Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al.: Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 2013, 53:57–61. 10.3960/jslrt.53.57
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A: European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005,90(8):1128–32.
Baserga M, Rosin M, Schoen M, Young G: Multifocal Castleman disease in pediatrics: case report. J Pediatr Hematol Oncol 2005, 27:666–9. 10.1097/01.mph.0000193468.06938.93
Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, et al.: The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman’s disease. BMC pediatrics 2014, 14:139. 10.1186/1471-2431-14-139
Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, et al.: Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia–a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 2013, 53:79–85. 10.3960/jslrt.53.79
Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, et al.: Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using Tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 2013, 52:1503–7. 10.2169/internalmedicine.52.9482
Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, et al.: Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop 2013, 53:87–93. 10.3960/jslrt.53.87
Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M: Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin a: a case report. J Clin Exp Hematop 2013, 53:95–9. 10.3960/jslrt.53.95
Ozawa T, Kosugi S, Kito M, Onishi M, Kida T, Nakata S, et al.: Efficacy of Rituximab for TAFRO syndrome, a variant type of multicentric Castleman's disease. Rinsho Ketsueki 2014, 55:350–5.
Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, et al.: Clinical features and treatment of multicentric castleman's disease: a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 2013, 53:69–77. 10.3960/jslrt.53.69
Van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z: Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010, 8:486–98.
Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, et al.: A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients. Med Oncol 2010, 27:1171–8. 10.1007/s12032-009-9355-0
Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD: Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001, 92:670–6. 10.1002/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-Q
Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al.: Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000, 95:56–61.
Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, et al.: Anti-interleukin-6 receptor antibody (Tocilizumab) treatment of Multicentric Castleman’s disease. Intern Med 2007, 46:771–4. 10.2169/internalmedicine.46.6262
Galeotti C, Boucheron A, Guillaume S, Koné-Paut I: Sustained remission of multicentric Castleman disease in children treated with Tocilizumab, an anti-interleukin-6 receptor antibody. Mol Cancer Ther 2012, 11:1623–6. 10.1158/1535-7163.MCT-11-0972
Turcotte LM, Correll CK, Reed RC, Moertel CL: Sustained remission of severe multicentric Castleman disease following multiagent chemotherapy and Tocilizumab maintenance. Pediatr Blood Cancer 2014, 61:737–9. 10.1002/pbc.24761
Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T: Long-term remission in HIV-negative patients with multicentric Castleman's disease using Rituximab. Eur J Haematol 2006, 76:119–23. 10.1111/j.1600-0609.2005.00570.x
Mian H, Leber B: Mixed variant multicentric Castleman disease treated with Rituximab: case report. J Pediatr Hematol Oncol 2010, 32:622. 10.1097/MPH.0b013e3181f000e2
Fragasso A, Mannarella C, Ciancio A, Calvario A, Scarasciulli ML: Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed by Rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease. Leuk Lymphoma 2008, 49:2224–6. 10.1080/10428190802389835
Zhu SH, Yu YH, Zhang Y, Sun JJ, Han DL, Li J: Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients. Med Oncol 2013, 30:492.
Abenza-Abildua MJ, Fuentes B, Diaz D, Royo A, Olea T, Aguilar-Amat MJ, et al.: Cyclophosphamide-induced reversible posterior leukoencephalopathy syndrome. BMJ Case Rep 2009., 2009: doi:10.1136/bcr.07.2008.0467. Epub 2009 May 25
Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA: Posterior Reversible Encephalopathy Syndrome: Associated Clinical and Radiologic Findings. Mayo Clin Proc 2010, 85:427–32. 10.4065/mcp.2009.0590